CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:CRON • CA22717L1013

3.6 CAD
+0.09 (+2.56%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall CRON gets a fundamental rating of 4 out of 10. We evaluated CRON against 33 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • CRON had positive earnings in the past year.
  • In the past year CRON had a positive cash flow from operations.
  • In the past 5 years CRON reported 4 times negative net income.
  • CRON had negative operating cash flow in 4 of the past 5 years.
CRON.CA Yearly Net Income VS EBIT VS OCF VS FCFCRON.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • CRON has a better Return On Assets (3.06%) than 78.79% of its industry peers.
  • With a decent Return On Equity value of 3.33%, CRON is doing good in the industry, outperforming 78.79% of the companies in the same industry.
Industry RankSector Rank
ROA 3.06%
ROE 3.33%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON.CA Yearly ROA, ROE, ROICCRON.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

  • With an excellent Profit Margin value of 27.27%, CRON belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
  • CRON's Profit Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 43.35%, CRON is in line with its industry, outperforming 57.58% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 27.27%
GM 43.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON.CA Yearly Profit, Operating, Gross MarginsCRON.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRON has been increased compared to 1 year ago.
  • CRON has more shares outstanding than it did 5 years ago.
  • CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON.CA Yearly Shares OutstandingCRON.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON.CA Yearly Total Debt VS Total AssetsCRON.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 7.80 indicates that CRON is not in any danger for bankruptcy at the moment.
  • CRON has a Altman-Z score of 7.80. This is amongst the best in the industry. CRON outperforms 93.94% of its industry peers.
  • There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.8
ROIC/WACCN/A
WACC8.61%
CRON.CA Yearly LT Debt VS Equity VS FCFCRON.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • CRON has a Current Ratio of 22.45. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
  • CRON's Current ratio of 22.45 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
  • CRON has a Quick Ratio of 21.28. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CRON (21.28) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 22.45
Quick Ratio 21.28
CRON.CA Yearly Current Assets VS Current LiabilitesCRON.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 283.33%, which is quite impressive.
  • CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
  • The Revenue has grown by 19.00% in the past year. This is quite good.
  • The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%

3.2 Future

  • CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
  • Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 7.39% on average per year.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRON.CA Yearly Revenue VS EstimatesCRON.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON.CA Yearly EPS VS EstimatesCRON.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.00, CRON is valued on the expensive side.
  • 75.76% of the companies in the same industry are more expensive than CRON, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 28.06. CRON is around the same levels.
  • With a Price/Forward Earnings ratio of 36.89, CRON can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 63.64% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (27.86), we can say CRON is valued slightly more expensively.
Industry RankSector Rank
PE 24
Fwd PE 36.89
CRON.CA Price Earnings VS Forward Price EarningsCRON.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON.CA Per share dataCRON.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRONOS GROUP INC

TSX:CRON (2/6/2026, 7:00:00 PM)

3.6

+0.09 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners15.01%
Inst Owner ChangeN/A
Ins Owners6.28%
Ins Owner ChangeN/A
Market Cap1.38B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target4.72 (31.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)-7.5%
PT rev (3m)96.81%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.07%
Revenue NQ rev (3m)-12.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.71%
Valuation
Industry RankSector Rank
PE 24
Fwd PE 36.89
P/S 7.62
P/FCF N/A
P/OCF 46.37
P/B 0.93
P/tB 1
EV/EBITDA N/A
EPS(TTM)0.15
EY4.17%
EPS(NY)0.1
Fwd EY2.71%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY2.16%
SpS0.47
BVpS3.86
TBVpS3.6
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.61
Profitability
Industry RankSector Rank
ROA 3.06%
ROE 3.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 27.27%
GM 43.35%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.86%
Cap/Sales 20.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.45
Quick Ratio 21.28
Altman-Z 7.8
F-Score6
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.92%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A

CRONOS GROUP INC / CRON.CA FAQ

What is the fundamental rating for CRON stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRON.CA.


What is the valuation status of CRONOS GROUP INC (CRON.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.


What is the profitability of CRON stock?

CRONOS GROUP INC (CRON.CA) has a profitability rating of 3 / 10.


What is the valuation of CRONOS GROUP INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CRONOS GROUP INC (CRON.CA) is 24 and the Price/Book (PB) ratio is 0.93.